What's in Gliknik Inc.'s pipeline?

Gliknik Inc. has 2 drugs in our index: 0 marketed, 0 filed, 0 in Phase 3, 1 in Phase 2, 1 in Phase 1.

Which companies overlap with Gliknik Inc.'s portfolio?

Top competitors by shared drug class: Agomab Spain S.L., Avalo Therapeutics, Inc., Bristol-Myers Squibb, Celltrion, Centocor, Inc..

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/gliknik-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-14 · How we verify

Gliknik Inc. — Portfolio Competitive Intelligence Brief

Gliknik Inc. pipeline: 0 marketed, 0 filed, 0 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 0 Phase 3 1 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

No leading-phase drugs tracked for this sponsor.

Therapeutic area mix

Oncology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Agomab Spain S.L. · 1 shared drug class
Avalo Therapeutics, Inc. · 1 shared drug class
Bristol-Myers Squibb · 1 shared drug class
Celltrion · 1 shared drug class
Centocor, Inc. · 1 shared drug class
Clinique des Céphalées de Montréal · 1 shared drug class
Dermira, Inc. · 1 shared drug class
European Organisation for Research and Treatment of Cancer - EORTC · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Gliknik Inc.:

Cite this brief

Drug Landscape (2026). Gliknik Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/gliknik-inc. Accessed 2026-05-14.